Get the Stockscreener App
35.19
2.57%
-0.93
Rigel Pharmaceuticals stock is traded at $35.19, with a volume of 583.43K.
It is down -2.57% in the last 24 hours and up +19.29% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$36.12
Open:
$35.37
24h Volume:
583.43K
Relative Volume:
0.83
Market Cap:
$631.21M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-251.36
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+11.43%
1M Performance:
+19.29%
6M Performance:
+90.53%
1Y Performance:
+127.91%
1-Day Range:
$34.64
$35.91
1-Week Range:
$28.08
$39.56
52-Week Range:
$14.63
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
35.19 | 655.63M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Will Rigel Pharmaceuticals Inc. (RI2) stock split increase liquidityJuly 2025 Patterns & Fast Moving Trade Plans - newser.com
Will Rigel Pharmaceuticals Inc. stock attract ESG investors2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
How the Story Behind Rigel Pharmaceuticals Is Evolving After Analyst Upgrades and New Guidance - Yahoo Finance
Will Rigel Pharmaceuticals Inc. (RI2) stock enhance shareholder value2025 Big Picture & Low Risk Entry Point Tips - newser.com
Will Rigel Pharmaceuticals Inc. stock reach Wall Street targets2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
Can Rigel Pharmaceuticals Inc. (RI2) stock ride next bull market cycleWeekly Trade Analysis & Daily Oversold Stock Bounce Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock remains undervaluedMarket Sentiment Report & High Accuracy Swing Entry Alerts - newser.com
How Rigel Pharmaceuticals Inc. stock responds to policy changesJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Applying big data sentiment scoring on Rigel Pharmaceuticals Inc.Fed Meeting & High Accuracy Swing Entry Alerts - newser.com
What insider trading reveals about Rigel Pharmaceuticals Inc. stockMarket Growth Summary & Stock Portfolio Risk Management - newser.com
Candlestick signals on Rigel Pharmaceuticals Inc. stock todayIndex Update & Safe Entry Zone Tips - newser.com
Rigel Pharmaceuticals (RIGL) Is Up 14.2% After Raising 2025 Revenue Guidance on Strong Q3 Results - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2025 Earnings Call Transcript - Insider Monkey
Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock - sharewise.com
All You Need to Know About Rigel (RIGL) Rating Upgrade to Strong Buy - Yahoo Finance Singapore
Top-Rated Stocks: Rigel Pharmaceuticals Sees Composite Rating Climb To 96 - MSN
Jefferies Upgrades Rigel Pharmaceuticals to Buy From Hold, Adjusts PT to $42 From $23 - MarketScreener
Rigel Pharmaceuticals (NASDAQ:RIGL) Rallies 29% This Week, Taking Three-year Gains to 465% - 富途牛牛
Will earnings trigger a reversal in Rigel Pharmaceuticals Inc.Gap Down & Weekly Setup with High ROI Potential - newser.com
Can Rigel Pharmaceuticals Inc. stock hit analyst price targets2025 Support & Resistance & Fast Entry Momentum Alerts - newser.com
Is Rigel Pharmaceuticals Inc. stock a contrarian buyBreakout Watch & Free Growth Oriented Trading Recommendations - newser.com
Jefferies Upgrades Rigel Pharmaceuticals (RIGL) - Nasdaq
Will Rigel Pharmaceuticals Inc. (RI2) stock outperform value peers2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
What machine learning models say about Rigel Pharmaceuticals Inc.Trade Ideas & Fast Moving Trade Plans - newser.com
Detecting price anomalies in Rigel Pharmaceuticals Inc. with AIDollar Strength & Reliable Breakout Forecasts - newser.com
Rigel Pharmaceuticals (RIGL) Profitability Rebound Reinforces Bullish Valuation Narratives - Yahoo Finance
What momentum shifts mean for Rigel Pharmaceuticals Inc.July 2025 Snapshot & AI Forecasted Stock Moves - newser.com
Can Rigel Pharmaceuticals Inc. (RI2) stock double in coming yearsJuly 2025 Decliners & Expert Approved Momentum Trade Ideas - newser.com
Jefferies Initiates Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Announces Target Price $42 - 富途牛牛
Rigel Pharmaceuticals upgraded to Buy at Jefferies on strong execution - TipRanks
What is the fair value estimate for Rigel Pharmaceuticals Inc. (RI2) stock in 2025Market Trend Summary & Accurate Trade Setup Notifications - newser.com
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Rigel Pharmaceuticals Reports Record Q3 Revenue and Growth - TipRanks
Is Rigel Pharmaceuticals Inc. stock recession proofMarket Rally & Weekly Top Stock Performers List - newser.com
Momentum divergence signals in Rigel Pharmaceuticals Inc. chart2025 Market Outlook & Fast Entry and Exit Trade Plans - newser.com
Why pension funds invest in Rigel Pharmaceuticals Inc. (RI2) stockPortfolio Return Summary & Weekly Momentum Picks - newser.com
Rigel Pharmaceuticals (RIGL) Turns Profitable, But Guidance for Earnings Decline Challenges Bullish Narratives - simplywall.st
Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Expectations By $0.53 EPS - MarketBeat
Jefferies upgrades Rigel Pharmaceuticals stock rating to Buy on strong sales - Investing.com India
Jefferies Upgrades RIGL Rating to "Buy" and Raises Price Target to $42 | RIGL Stock News - GuruFocus
Rigel Pharmaceuticals’ Shares Skyrocket: Analyzing Market Impact - timothysykes.com
Rigel Pharmaceuticals (RIGL) Surges 31% on Strong Q3 Results and Guidance Boost - GuruFocus
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats - Seeking Alpha
Cantor Fitzgerald Maintains Neutral Rating, Raises Price Target for RIGL | RIGL Stock News - GuruFocus
Rigel raises 2025 revenue guidance to $285M–$290M as commercial sales growth accelerates - MSN
Lilly inks AI-engineered bispecifics deal with XtalPi, exits CNS tie-up with Rigel - FirstWord Pharma
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):